Tissue Engineering and Regeneration: Technologies and Global Markets
REPORT SCOPE:
This report covers all revenues earned by regeneration therapies. These therapies are extensively used to replace and regenerate the cells, genes and tissues in a patient’s body. The report considers revenue generated by products and services in the regenerative medicine market. Services include tools, along with cell and gene bank charges, where the cells and tissues are stored and treated properly pre- and post-experimentation and treatment. The report also covers revenues earned by small molecules and biologics (drugs) that speed up the regeneration process. Other drug therapy revenues (e.g., painkillers, analgesics) that can be used along with regenerative therapy are not included in the report, as they do not contribute to cell or tissue regeneration. The report covers all existing applications of regenerative medicine therapy.
The global tissue engineering and regeneration market is primarily categorized by segment, material, application and region. The major segments are therapeutic products, tools, banks and services. Therapeutic products are further segmented into cell therapy, gene therapy, tissue engineering, and small molecules and biologics based on product type. Therapeutic products are also categorized into synthetic materials, biologically derived materials, genetically engineered materials, and small molecules and biologics based on material. The report includes key technologies involved in regenerative medicine therapy. The study analyzes clinical trials and patents in different regions. The report provides an in-depth analysis of key companies operating in the global tissue engineering and regeneration market.
By region, the market is segmented into North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Advanced Cell Technology, Arteriocyte, Athersys, Bioheart, BioMimetic Therapeutics, BioTissue Technologies, Cerapedics, Cook Biotech, CryoLife, Cytograft Tissue Engineering, Cytomedix, Cytori Therapeutics, Genzyme/Sanofi, Integra LifeSciences, International Stem Cell, LifeCell/Kinetic Concepts and Mesoblast.
REPORT INCLUDES:
This report covers all revenues earned by regeneration therapies. These therapies are extensively used to replace and regenerate the cells, genes and tissues in a patient’s body. The report considers revenue generated by products and services in the regenerative medicine market. Services include tools, along with cell and gene bank charges, where the cells and tissues are stored and treated properly pre- and post-experimentation and treatment. The report also covers revenues earned by small molecules and biologics (drugs) that speed up the regeneration process. Other drug therapy revenues (e.g., painkillers, analgesics) that can be used along with regenerative therapy are not included in the report, as they do not contribute to cell or tissue regeneration. The report covers all existing applications of regenerative medicine therapy.
The global tissue engineering and regeneration market is primarily categorized by segment, material, application and region. The major segments are therapeutic products, tools, banks and services. Therapeutic products are further segmented into cell therapy, gene therapy, tissue engineering, and small molecules and biologics based on product type. Therapeutic products are also categorized into synthetic materials, biologically derived materials, genetically engineered materials, and small molecules and biologics based on material. The report includes key technologies involved in regenerative medicine therapy. The study analyzes clinical trials and patents in different regions. The report provides an in-depth analysis of key companies operating in the global tissue engineering and regeneration market.
By region, the market is segmented into North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Advanced Cell Technology, Arteriocyte, Athersys, Bioheart, BioMimetic Therapeutics, BioTissue Technologies, Cerapedics, Cook Biotech, CryoLife, Cytograft Tissue Engineering, Cytomedix, Cytori Therapeutics, Genzyme/Sanofi, Integra LifeSciences, International Stem Cell, LifeCell/Kinetic Concepts and Mesoblast.
REPORT INCLUDES:
- 59 data tables and 56 additional tables
- An overview of the global market for tissue engineering and regeneration technologies within the industry
- Analysis of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- A look at the future trends, products details, and therapies available in the field of tissue engineering
- Evaluation of the competitive environments, including new and potential markets for novel therapies and treatments
- Coverage of regulatory dynamics, pipeline analysis, patent analysis, and market drivers, restrains, and opportunities
- Comprehensive company profiles of leading market players, including Ocata Therapeutics, Inc. (Astellas Pharma, Inc.), Co.don AG, Cook Medical Inc., Cytori Therapeutics, Inc., and Kinetic Concepts, Inc. (KCI)
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Scope of Report
Intended Audience
Source of Information and Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Progress and Promises for Tissue-Engineering Industry
Body Parts That Can be Replaced by Tissue Engineering
Nanotechnology for Tissue Regeneration
Effects of Nanotechnology on Stem Cell Behavior for Tissue Regeneration
Nanotechnology in Tissue Regeneration Applications
Gene Therapies: The Future of Tissue Engineering
Progress
Prospects
Stem Cell Technologies Boon to Tissue Engineering
Regulatory Environment
Country-Specific Regulations
Regulatory Differences
Ethical Issues of Stem Cell Therapies and Cord Blood Banking
The Principle of Proportionality That Balances Means and Objectives
Impact of Healthcare System on Tissue-Engineering Market Development
Bioprinting Technology in Regenerative Medicine
Porter's Five Forces Analysis of Tissue Engineering and Regeneration Market
Moderate Bargaining Power of Supplier
Low Bargaining Power of Buyer
Moderate to Low Level of Threats from Substitute Products
Low to Moderate Threat of New Entrants
Clinical Trials
U.S. Clinical Trials for Tissue Engineering and Regenerative Medicine
European Clinical Trials for Tissue Engineering and Regenerative Medicine
Asian Clinical Trials for Tissue Engineering and Regenerative Medicine
Market Dynamics
Drivers
Restraints
Opportunities in Stem Cell Applications
CHAPTER 4 MARKET BREAKDOWN BY SEGMENT
Therapeutic Products
Cell Therapy
Tissue Vascularization
Cell Culturing
Small Molecules and Biologics
Tissue Engineering
Gene Therapy
CHAPTER 5 MARKET BREAKDOWN BY MATERIAL
Synthetic Materials
Biodegradable Synthetic Polymers
Scaffolds: Medical Poly Lactic Acid
Artificial Vascular Graft Materials
Hydrogel Technology
Biologically Derived Materials
Collagen
Xenogenic Tissue
Genetically Engineered Materials
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Cardiovascular Disorders
Peripheral Vascular Disease Applications
Coronary Artery Disease
Oncology
Dermatology
Musculoskeletal
Orthopedics
Bone Repair and Replacement
Cartilage and Connective Tissue Damage
CHAPTER 7 MARKET BREAKDOWN BY REGION
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Other European Countries
Asia-Pacific
India
Japan
China
Australia
Rest of Asia-Pacific
Rest of World
Cartilage and Bone Tissue-Engineering Products
Cardiovascular Disease Products
Central Nervous System-Related Injuries and Diseases
CHAPTER 8 COMPETITIVE LANDSCAPE
Approvals
Agreements, Expansions and Collaborations
Product Launches and Patent Applications/Patent Approvals
Mergers and Acquisitions
CHAPTER 9 PATENT ANALYSIS
Japanese Patent Analysis
European Patent Analysis
U.S. Patent Analysis
CHAPTER 10 COMPANY PROFILES
ARTERIOCYTE MEDICAL SYSTEMS INC. (ISTO BIOLOGICS)
ATHERSYS INC.
CERAPEDICS, INC.
CO.DON AG
COOK MEDICAL INC.
CRYOLIFE, INC.
CYTORI THERAPEUTICS, INC.
GENZYME CORP.
KINETIC CONCEPTS, INC.
MESOBLAST LTD.
NUO THERAPEUTICS, INC. (CYTOMEDIX, INC.)
OCATA THERAPEUTICS, INC. (ASTELLAS PHARMA, INC.)
ORGANOGENESIS INC. (ADVANCED BIOHEALING)
ORTHOPEUTICS LP
U.S. STEM CELL, INC. (BIOHEART INC.)
VERICEL CORP. (AASTROM BIOSCIENCES INC.)
WRIGHT MEDICAL GROUP N.V.
Study Goals and Objectives
Scope of Report
Intended Audience
Source of Information and Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Progress and Promises for Tissue-Engineering Industry
Body Parts That Can be Replaced by Tissue Engineering
Nanotechnology for Tissue Regeneration
Effects of Nanotechnology on Stem Cell Behavior for Tissue Regeneration
Nanotechnology in Tissue Regeneration Applications
Gene Therapies: The Future of Tissue Engineering
Progress
Prospects
Stem Cell Technologies Boon to Tissue Engineering
Regulatory Environment
Country-Specific Regulations
Regulatory Differences
Ethical Issues of Stem Cell Therapies and Cord Blood Banking
The Principle of Proportionality That Balances Means and Objectives
Impact of Healthcare System on Tissue-Engineering Market Development
Bioprinting Technology in Regenerative Medicine
Porter's Five Forces Analysis of Tissue Engineering and Regeneration Market
Moderate Bargaining Power of Supplier
Low Bargaining Power of Buyer
Moderate to Low Level of Threats from Substitute Products
Low to Moderate Threat of New Entrants
Clinical Trials
U.S. Clinical Trials for Tissue Engineering and Regenerative Medicine
European Clinical Trials for Tissue Engineering and Regenerative Medicine
Asian Clinical Trials for Tissue Engineering and Regenerative Medicine
Market Dynamics
Drivers
Restraints
Opportunities in Stem Cell Applications
CHAPTER 4 MARKET BREAKDOWN BY SEGMENT
Therapeutic Products
Cell Therapy
Tissue Vascularization
Cell Culturing
Small Molecules and Biologics
Tissue Engineering
Gene Therapy
CHAPTER 5 MARKET BREAKDOWN BY MATERIAL
Synthetic Materials
Biodegradable Synthetic Polymers
Scaffolds: Medical Poly Lactic Acid
Artificial Vascular Graft Materials
Hydrogel Technology
Biologically Derived Materials
Collagen
Xenogenic Tissue
Genetically Engineered Materials
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Cardiovascular Disorders
Peripheral Vascular Disease Applications
Coronary Artery Disease
Oncology
Dermatology
Musculoskeletal
Orthopedics
Bone Repair and Replacement
Cartilage and Connective Tissue Damage
CHAPTER 7 MARKET BREAKDOWN BY REGION
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Other European Countries
Asia-Pacific
India
Japan
China
Australia
Rest of Asia-Pacific
Rest of World
Cartilage and Bone Tissue-Engineering Products
Cardiovascular Disease Products
Central Nervous System-Related Injuries and Diseases
CHAPTER 8 COMPETITIVE LANDSCAPE
Approvals
Agreements, Expansions and Collaborations
Product Launches and Patent Applications/Patent Approvals
Mergers and Acquisitions
CHAPTER 9 PATENT ANALYSIS
Japanese Patent Analysis
European Patent Analysis
U.S. Patent Analysis
CHAPTER 10 COMPANY PROFILES
ARTERIOCYTE MEDICAL SYSTEMS INC. (ISTO BIOLOGICS)
ATHERSYS INC.
CERAPEDICS, INC.
CO.DON AG
COOK MEDICAL INC.
CRYOLIFE, INC.
CYTORI THERAPEUTICS, INC.
GENZYME CORP.
KINETIC CONCEPTS, INC.
MESOBLAST LTD.
NUO THERAPEUTICS, INC. (CYTOMEDIX, INC.)
OCATA THERAPEUTICS, INC. (ASTELLAS PHARMA, INC.)
ORGANOGENESIS INC. (ADVANCED BIOHEALING)
ORTHOPEUTICS LP
U.S. STEM CELL, INC. (BIOHEART INC.)
VERICEL CORP. (AASTROM BIOSCIENCES INC.)
WRIGHT MEDICAL GROUP N.V.
LIST OF TABLES
Summary Table: Global Market for Tissue Engineering and Regeneration, by Region, Through 2023
Table 1: U.S. and European Differences in Regulatory Approval
Table 2: Main Aspects of Healthcare Provisions in Different Countries
Table 3: Active U.S. Clinical Trials for Tissue Engineering and Regenerative Medicine, 2015-2019
Table 4: Active European Clinical Trials Being Conducted for Tissue Engineering and Regenerative Medicine, 2015-2019
Table 5: Active Asian Clinical Trials for Tissue Engineering and Regenerative Medicine, 2015-2019
Table 6: Number of Clinical Trials Registered for Various Diseases, 2011-2016
Table 7: Application of Stem Cells in Regenerative Medicine
Table 8: Global Market for Tissue Engineering and Regeneration, by Segment, Through 2023
Table 9: Global Market for Tissue Engineering and Regeneration, by Therapeutic Product, Through 2023
Table 10: Autologous vs. Allogenic Cells: Manufacturing Process
Table 11: Global Market for Cell Therapy, by Region, Through 2023
Table 12: Stem Cells, Advantages and Clinical Trials on Cardiovascular Disease Treatments
Table 13: Types of Urinary Bladder Scaffolds Proposed, 2011-2017
Table 14: Investments in Cell Culture Technology, 2017-2018
Table 15: Projects and Their Assessment Stages, 2017
Table 16: Global Market for Small Molecules and Biologics, by Region, Through 2023
Table 17: FDA New Molecular Entity Approval Attributes, 2017 and 2018
Table 18: Global Market for Tissue-Engineering, by Region, Through 2023
Table 19: Global Market for Gene Therapy, by Region, Through 2023
Table 20: Global Market for Tissue Engineering and Regeneration, by Therapeutic Material, Through 2023
Table 21: Global Market for Synthetic Materials, by Type, Through 2023
Table 22: Global Market for Synthetic Materials, by Region, Through 2023
Table 23: Biodegradable Polymer Classification
Table 24: Global Market for Biodegradable Synthetic Polymers, by Region, Through 2023
Table 25: Commercial Polymeric Scaffold Products
Table 26: Global Market for Scaffolds, by Region, Through 2023
Table 27: Tissue Engineered Vascular Graft Utilized in Human Studies, 2011-2017
Table 28: Global Market for Artificial Vascular Grafts, by Region, Through 2023
Table 29: Global Market for Hydrogel Technology, by Region, Through 2023
Table 30: Global Market for Biologically Derived Materials, by Type, Through 2023
Table 31: Global Market for Biologically Derived Materials, by Region, Through 2023
Table 32: Global Market for Biologically Derived Collagen, by Region, Through 2023
Table 33: Commercially Available Xenogeneic Acellular Graft
Table 34: Global Market for Biologically Derived Xenogenic Tissue, by Region, Through 2023
Table 35: Global Market for Genetically Engineered Materials, by Type, Through 2023
Table 36: Global Market for Genetically Engineered Materials, by Region, Through 2023
Table 37: Global Market for Deoxyribonucleic Acid Transfection Vectors, by Region, Through 2023
Table 38: Global Market for Genetically Manipulated Cells, by Region, Through 2023
Table 39: Global Market for 3D Polymer Technology, by Region, Through 2023
Table 40: List of Polymer Scaffolds Fabricated for Tissue Engineering Utilizing 3D Printing
Table 41: Global Market for Transgenics in Tissue Engineering, by Region, Through 2023
Table 42: Global Market for Fibroblasts, by Region, Through 2023
Table 43: Commercially Available Fibroblast Based Skin Substitute
Table 44: Global Market for Neural Stem Cells, by Region, Through 2023
Table 45: Global Market for Gene-Activated Matrix, by Region, Through 2023
Table 46: List of Biologics Approved, 2017
Table 47: Global Market for Small Molecules and Biologics, by Region, Through 2023
Table 48: Global Market for Tissue Engineering and Regeneration, by Application, Through 2023
Table 49: Global Market for Tissue-Engineering and Regeneration in Cardiovascular Applications, by Region, Through 2023
Table 50: Cell Therapies by Different Companies to Treat Cardiovascular Diseases
Table 51: Global Market for Tissue-Engineering and Regeneration in Oncology, by Region, Through 2023
Table 52: Global and U.S. Statistics for Skin Damage Medical Conditions, 2018
Table 53: Acellular Skin Tissue-Engineered Products in the Market
Table 54: Cellular Skin Tissue-Engineered Products in the Market
Table 55: Global Market for Tissue-Engineering and Regeneration in Dermatology Applications, by Region, Through 2023
Table 56: Global Market for Tissue-Engineering and Regeneration in Musculoskeletal Applications, by Region, Through 2023
Table 57: Orthopedic Diseases, by Region: Key Facts
Table 58: Regenerative Medicine Companies, by Size and Region, 2011
Table 59: Global Market for Tissue-Engineering and Regeneration, by Region, Through 2023
Table 60: North American Commercialized Tissue-Engineering Products
Table 61: North American Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
Table 62: Tissue Engineering Research Conducted according to Different Universities
Table 63: Tissue-Engineering Products Offered by Different Companies
Table 64: Funds Allocated for Research Activities in Budget, 2016
Table 65: Share of Increase of Spending on Biologics in Canada, 2011-2016
Table 66: Shares of Tissue-Engineering Firms in Selected European Countries, 2016
Table 67: European Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
Table 68: Number of Deaths across Germany on Gender Differentiation, by Cause of Death, 2017
Table 69: Companies That Target Different Tissue-Engineering Areas in Germany
Table 70: Different Causes of Death: U.K. Statistics, 2017
Table 71: Companies That Target Different Tissue Engineering Areas in the U.K.
Table 72: Companies That Target Different Tissue Engineering Areas in France
Table 73: European Stem Cell Policies, by Country
Table 74: European Companies Developing Products in Tissue Engineering and Regeneration for Central Nervous System Disorders and Injuries
Table 75: Asia-Pacific Market for Tissue Engineering and Regeneration, by Segment, Through 2023
Table 76: Rest of World Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
Table 77: Global Statistics for Central Nervous System Disorders and Injuries, 2015
Table 78: Key Competitive Strategies Used in the Tissue-Engineering Market, by Development Type, 2016-2019
Table 79: Regulatory Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Table 80: Key Approvals in the Tissue-Engineering Market, 2016-2019
Table 81: Shares of Agreements, Expansions and Collaborations in the Tissue-Engineering Market, by Company, 2016-2019
Table 82: Key Agreements, Expansions and Collaborations in the Tissue-Engineering Market, 2016-2019
Table 83: Shares of Product Launches and Patent Applications/Patent Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Table 84: Key Product Launches in the Tissue-Engineering Market, 2016-2019
Table 85: Shares of Mergers and Acquisitions in the Tissue-Engineering Market, by Company, 2016-2019
Table 86: Key Mergers and Acquisitions in the Tissue-Engineering Market, 2016-2019
Table 87: Japanese Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
Table 88: European Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
Table 89: U.S. Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
Table 90: Isto Biologics: Recent Developments
Table 91: Athersys Inc.: Financials, 2015-2017
Table 92: Athersys Inc.: Recent Developments
Table 93: Cerapedics, Inc.: Recent Developments
Table 94: Co.don AG: Recent Developments
Table 95: Cook Medical Inc.: Recent Developments
Table 96: CryoLife, Inc.: Financials, 2015-2017
Table 97: CryoLife, Inc.: Recent Developments
Table 98: Cytori Therapeutics, Inc.: Financials, 2013-2015
Table 99: Cytori Therapeutics, Inc.: Recent Developments
Table 100: Genzyme Corp.: Financials, 2013-2015
Table 101: Genzyme Corp.: Recent Developments
Table 102: Kinetic Concepts, Inc.: Recent Developments
Table 103: Mesoblast Ltd.: Financials, 2013-2015
Table 104: Mesoblast Ltd.: Recent Developments
Table 105: Nuo Therapeutics, Inc.: Financials, 2013-2015
Table 106: Astella Pharma, Inc.: Recent Developments
Table 107: Organogenesis Inc.: Recent Developments
Table 108: Orthopeutics LP: Recent Developments
Table 109: U.S. Stem Cell, Inc.: Financials, 2016-2018
Table 110: U.S. Stem Cell, Inc.: Recent Developments
Table 111: Vericel Corp.: Financials, 2016-2018
Table 112: Vericel Corp.: Recent Developments
Table 113: Wright Medical Group N.V.: Financials, 2016-2018
Table 114: Wright Medical Technology Inc.: Recent Developments
Summary Table: Global Market for Tissue Engineering and Regeneration, by Region, Through 2023
Table 1: U.S. and European Differences in Regulatory Approval
Table 2: Main Aspects of Healthcare Provisions in Different Countries
Table 3: Active U.S. Clinical Trials for Tissue Engineering and Regenerative Medicine, 2015-2019
Table 4: Active European Clinical Trials Being Conducted for Tissue Engineering and Regenerative Medicine, 2015-2019
Table 5: Active Asian Clinical Trials for Tissue Engineering and Regenerative Medicine, 2015-2019
Table 6: Number of Clinical Trials Registered for Various Diseases, 2011-2016
Table 7: Application of Stem Cells in Regenerative Medicine
Table 8: Global Market for Tissue Engineering and Regeneration, by Segment, Through 2023
Table 9: Global Market for Tissue Engineering and Regeneration, by Therapeutic Product, Through 2023
Table 10: Autologous vs. Allogenic Cells: Manufacturing Process
Table 11: Global Market for Cell Therapy, by Region, Through 2023
Table 12: Stem Cells, Advantages and Clinical Trials on Cardiovascular Disease Treatments
Table 13: Types of Urinary Bladder Scaffolds Proposed, 2011-2017
Table 14: Investments in Cell Culture Technology, 2017-2018
Table 15: Projects and Their Assessment Stages, 2017
Table 16: Global Market for Small Molecules and Biologics, by Region, Through 2023
Table 17: FDA New Molecular Entity Approval Attributes, 2017 and 2018
Table 18: Global Market for Tissue-Engineering, by Region, Through 2023
Table 19: Global Market for Gene Therapy, by Region, Through 2023
Table 20: Global Market for Tissue Engineering and Regeneration, by Therapeutic Material, Through 2023
Table 21: Global Market for Synthetic Materials, by Type, Through 2023
Table 22: Global Market for Synthetic Materials, by Region, Through 2023
Table 23: Biodegradable Polymer Classification
Table 24: Global Market for Biodegradable Synthetic Polymers, by Region, Through 2023
Table 25: Commercial Polymeric Scaffold Products
Table 26: Global Market for Scaffolds, by Region, Through 2023
Table 27: Tissue Engineered Vascular Graft Utilized in Human Studies, 2011-2017
Table 28: Global Market for Artificial Vascular Grafts, by Region, Through 2023
Table 29: Global Market for Hydrogel Technology, by Region, Through 2023
Table 30: Global Market for Biologically Derived Materials, by Type, Through 2023
Table 31: Global Market for Biologically Derived Materials, by Region, Through 2023
Table 32: Global Market for Biologically Derived Collagen, by Region, Through 2023
Table 33: Commercially Available Xenogeneic Acellular Graft
Table 34: Global Market for Biologically Derived Xenogenic Tissue, by Region, Through 2023
Table 35: Global Market for Genetically Engineered Materials, by Type, Through 2023
Table 36: Global Market for Genetically Engineered Materials, by Region, Through 2023
Table 37: Global Market for Deoxyribonucleic Acid Transfection Vectors, by Region, Through 2023
Table 38: Global Market for Genetically Manipulated Cells, by Region, Through 2023
Table 39: Global Market for 3D Polymer Technology, by Region, Through 2023
Table 40: List of Polymer Scaffolds Fabricated for Tissue Engineering Utilizing 3D Printing
Table 41: Global Market for Transgenics in Tissue Engineering, by Region, Through 2023
Table 42: Global Market for Fibroblasts, by Region, Through 2023
Table 43: Commercially Available Fibroblast Based Skin Substitute
Table 44: Global Market for Neural Stem Cells, by Region, Through 2023
Table 45: Global Market for Gene-Activated Matrix, by Region, Through 2023
Table 46: List of Biologics Approved, 2017
Table 47: Global Market for Small Molecules and Biologics, by Region, Through 2023
Table 48: Global Market for Tissue Engineering and Regeneration, by Application, Through 2023
Table 49: Global Market for Tissue-Engineering and Regeneration in Cardiovascular Applications, by Region, Through 2023
Table 50: Cell Therapies by Different Companies to Treat Cardiovascular Diseases
Table 51: Global Market for Tissue-Engineering and Regeneration in Oncology, by Region, Through 2023
Table 52: Global and U.S. Statistics for Skin Damage Medical Conditions, 2018
Table 53: Acellular Skin Tissue-Engineered Products in the Market
Table 54: Cellular Skin Tissue-Engineered Products in the Market
Table 55: Global Market for Tissue-Engineering and Regeneration in Dermatology Applications, by Region, Through 2023
Table 56: Global Market for Tissue-Engineering and Regeneration in Musculoskeletal Applications, by Region, Through 2023
Table 57: Orthopedic Diseases, by Region: Key Facts
Table 58: Regenerative Medicine Companies, by Size and Region, 2011
Table 59: Global Market for Tissue-Engineering and Regeneration, by Region, Through 2023
Table 60: North American Commercialized Tissue-Engineering Products
Table 61: North American Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
Table 62: Tissue Engineering Research Conducted according to Different Universities
Table 63: Tissue-Engineering Products Offered by Different Companies
Table 64: Funds Allocated for Research Activities in Budget, 2016
Table 65: Share of Increase of Spending on Biologics in Canada, 2011-2016
Table 66: Shares of Tissue-Engineering Firms in Selected European Countries, 2016
Table 67: European Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
Table 68: Number of Deaths across Germany on Gender Differentiation, by Cause of Death, 2017
Table 69: Companies That Target Different Tissue-Engineering Areas in Germany
Table 70: Different Causes of Death: U.K. Statistics, 2017
Table 71: Companies That Target Different Tissue Engineering Areas in the U.K.
Table 72: Companies That Target Different Tissue Engineering Areas in France
Table 73: European Stem Cell Policies, by Country
Table 74: European Companies Developing Products in Tissue Engineering and Regeneration for Central Nervous System Disorders and Injuries
Table 75: Asia-Pacific Market for Tissue Engineering and Regeneration, by Segment, Through 2023
Table 76: Rest of World Market for Tissue-Engineering and Regeneration, by Segment, Through 2023
Table 77: Global Statistics for Central Nervous System Disorders and Injuries, 2015
Table 78: Key Competitive Strategies Used in the Tissue-Engineering Market, by Development Type, 2016-2019
Table 79: Regulatory Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Table 80: Key Approvals in the Tissue-Engineering Market, 2016-2019
Table 81: Shares of Agreements, Expansions and Collaborations in the Tissue-Engineering Market, by Company, 2016-2019
Table 82: Key Agreements, Expansions and Collaborations in the Tissue-Engineering Market, 2016-2019
Table 83: Shares of Product Launches and Patent Applications/Patent Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Table 84: Key Product Launches in the Tissue-Engineering Market, 2016-2019
Table 85: Shares of Mergers and Acquisitions in the Tissue-Engineering Market, by Company, 2016-2019
Table 86: Key Mergers and Acquisitions in the Tissue-Engineering Market, 2016-2019
Table 87: Japanese Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
Table 88: European Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
Table 89: U.S. Patents and Patent Applications on Tissue-Engineering and Regeneration Technologies, 2016-February 2019
Table 90: Isto Biologics: Recent Developments
Table 91: Athersys Inc.: Financials, 2015-2017
Table 92: Athersys Inc.: Recent Developments
Table 93: Cerapedics, Inc.: Recent Developments
Table 94: Co.don AG: Recent Developments
Table 95: Cook Medical Inc.: Recent Developments
Table 96: CryoLife, Inc.: Financials, 2015-2017
Table 97: CryoLife, Inc.: Recent Developments
Table 98: Cytori Therapeutics, Inc.: Financials, 2013-2015
Table 99: Cytori Therapeutics, Inc.: Recent Developments
Table 100: Genzyme Corp.: Financials, 2013-2015
Table 101: Genzyme Corp.: Recent Developments
Table 102: Kinetic Concepts, Inc.: Recent Developments
Table 103: Mesoblast Ltd.: Financials, 2013-2015
Table 104: Mesoblast Ltd.: Recent Developments
Table 105: Nuo Therapeutics, Inc.: Financials, 2013-2015
Table 106: Astella Pharma, Inc.: Recent Developments
Table 107: Organogenesis Inc.: Recent Developments
Table 108: Orthopeutics LP: Recent Developments
Table 109: U.S. Stem Cell, Inc.: Financials, 2016-2018
Table 110: U.S. Stem Cell, Inc.: Recent Developments
Table 111: Vericel Corp.: Financials, 2016-2018
Table 112: Vericel Corp.: Recent Developments
Table 113: Wright Medical Group N.V.: Financials, 2016-2018
Table 114: Wright Medical Technology Inc.: Recent Developments
LIST OF FIGURES
Summary Figure: Global Market for Tissue Engineering and Regeneration, by Region, 2018-2023
Figure 1: Tissue-Engineering Strategies
Figure 2: Nanotechnology and Tissue Regeneration
Figure 3: Porter's Five Forces Model for Tissue-Engineering and Regenerative Medicine Market
Figure 4: Number of Clinical Trials Registered for Various Diseases, 2011-2016
Figure 5: FDA Approvals of Biologics, 2016-2018
Figure 6: Shares of Global Diabetes Prevalence, by Region, 2017
Figure 7: T-Cell Therapy Technique
Figure 8: Global Number of Orthopedic Surgeries, 2012-2020
Figure 9: Regenerative Medicine Companies, by Size and Region, 2011
Figure 10: United States’ NIH Stem Cell Research Spending, 2013-2018
Figure 11: Shares of Heart Disease Deaths in the U.S., by Disease Type, 2017
Figure 12: Healthcare Spending in Germany, by Source, 2015 and 2040 (est.)
Figure 13: Pathway for Dissemination of Regenerative Medicine
Figure 14: Shares of Key Competitive Strategies Used in the Tissue-Engineering Market, by Development Type, 2016-2019*
Figure 15: Shares of Regulatory Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Figure 16: Shares of Agreements, Expansions and Collaborations in the Tissue-Engineering Market, by Company, 2016-2019
Figure 17: Shares of Product Launches and Patent Applications/Patent Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Figure 18: Shares of Mergers and Acquisitions in the Tissue-Engineering Market, by Company, 2016-2019
Summary Figure: Global Market for Tissue Engineering and Regeneration, by Region, 2018-2023
Figure 1: Tissue-Engineering Strategies
Figure 2: Nanotechnology and Tissue Regeneration
Figure 3: Porter's Five Forces Model for Tissue-Engineering and Regenerative Medicine Market
Figure 4: Number of Clinical Trials Registered for Various Diseases, 2011-2016
Figure 5: FDA Approvals of Biologics, 2016-2018
Figure 6: Shares of Global Diabetes Prevalence, by Region, 2017
Figure 7: T-Cell Therapy Technique
Figure 8: Global Number of Orthopedic Surgeries, 2012-2020
Figure 9: Regenerative Medicine Companies, by Size and Region, 2011
Figure 10: United States’ NIH Stem Cell Research Spending, 2013-2018
Figure 11: Shares of Heart Disease Deaths in the U.S., by Disease Type, 2017
Figure 12: Healthcare Spending in Germany, by Source, 2015 and 2040 (est.)
Figure 13: Pathway for Dissemination of Regenerative Medicine
Figure 14: Shares of Key Competitive Strategies Used in the Tissue-Engineering Market, by Development Type, 2016-2019*
Figure 15: Shares of Regulatory Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Figure 16: Shares of Agreements, Expansions and Collaborations in the Tissue-Engineering Market, by Company, 2016-2019
Figure 17: Shares of Product Launches and Patent Applications/Patent Approvals in the Tissue-Engineering Market, by Company, 2016-2019
Figure 18: Shares of Mergers and Acquisitions in the Tissue-Engineering Market, by Company, 2016-2019
